As HIV meds mature, Gilead preps for HCV launch

Share this article:
Gilead shows latest on GT-1 all-oral
Gilead shows latest on GT-1 all-oral

Gilead saw a 15% hike in third-quarter revenue compared to the year-ago period, to $2.8 billion, the company reported. The Foster City, CA, biotech also noted in a conference call that it would add 150 reps in the US in preparation for the launch of hepatitis C drug sofosbuvir.

Gilead's sales were boosted by the antiviral franchise, particularly Stribild, or the "quad pill," whose sales have matured after launching in August 2012. The HIV treatment generated $143 million in sales, compared to $17 million in the same three month-period a year ago. Antiviral Complera/Eviplera also saw strong sales, with a 112% jump to $210 million, compared to $99 million a year ago. Antiviral products on the whole saw a 14% increase from last year's third quarter.

As the company gears up to launch HCV drug sofosbuvir, SG&A expenses rose by 27%, from $319 million in Q3 2012 to $407 million in the most recent quarter. The drug recently garnered a unanimous vote in favor of approval for patients with various genotypes of the disease, many of whom are being warehoused until approval.

Gilead declined to share an updated figure for the number of HCV patients who are diagnosed and under care from a specialist. ISI Group analyst Mark Schoenebaum, in an investor note yesterday, recalled that an earlier Gilead estimate had put the figure at 350,000. The analyst added that Gilead had lowered its estimate of HCV patients in the big five EU countries down by about a million patients, but had raised its US estimate by a million.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...